Skip to content
Screener

EPS (Diluted) at other companies

Merck & Co. logo
Merck & Co.MRK
-$0.54-131%
Amgen logo
AmgenAMGN
$4.37+64.9%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$12.23-4.5%
RFL
Rafael Holdings, Inc.RFL
-$0.08+57.9%
Denali Therapeutics Inc. logo
Denali Therapeutics Inc.DNLI
-$0.68+5.6%
Arvinas logo
ArvinasARVN
-$0.90-179%

Other financials

Income statement

See full
Revenue$3.7M-80.7%
Operating income-$64.9M-82.0%
Net income-$64.1M-269%

Balance sheet

See full
Cash & equivalents$424.2M-24.8%
Total debt$82.0K-75.0%
Total equity$631.4M-18.9%
Total assets$704.5M-13.6%

Cash flow

See full
Operating cash flow-$39.2M-4.1%
CapEx$80.0K-9.1%
Free cash flow-$39.3M-4.1%

Valuation

See full
Market cap$3.31B+24.7%
Enterprise value$2.88B+38.1%
P/S464.5×+423×

Profitability

See full
Operating margin-3,432.2%-3,753pp
Net margin-3,644.2%-3,946pp
FCF margin-2,018.3%-2,259pp

Returns & leverage

See full
Return on equity-36.8%+15.4pp
Debt / equity0.0×
Current ratio-12.1×

Where this comes from

Reported directly by NewAmsterdam Pharma Company in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The source filing: NewAmsterdam Pharma Company’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 7:06 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-333824
Line itemFor the three months ended June 30, 2026For the three months ended June 30, 2025For the six months ended June 30, 2026For the six months ended June 30, 2025
Loss before tax(64,135)(17,364)(112,576)(56,891)
Income tax expense
Loss for the period(64,135)(17,364)(112,576)(56,891)
Other comprehensive income/(loss)
Unrealized gain/(loss) on available-for-sale securities, net of tax(360)(107)(932)(140)
Total comprehensive loss for the period, net of tax(64,495)(17,471)(113,508)(57,031)
Net loss per ordinary share
Basic and diluted$(0.52)$(0.15)$(0.92)$(0.48)

Item 1. Financial Statements.

FAQ

What is NewAmsterdam Pharma Company's EPS (diluted)?
NewAmsterdam Pharma Company (NAMS) reported EPS (diluted) of -$0.52 in Q2 2026.
How has NewAmsterdam Pharma Company's EPS (diluted) changed year-over-year?
NewAmsterdam Pharma Company's EPS (diluted) decreased by 246.7% year-over-year, from -$0.15 to -$0.52.
What is the long-term trend for NewAmsterdam Pharma Company's EPS (diluted)?
Over 4 years (2021 to 2025), NewAmsterdam Pharma Company's EPS (diluted) has grown at a -17.9% compound annual growth rate (CAGR), from -$3.81 to -$1.73.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.

Ask your AI about NewAmsterdam Pharma Company's eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude